Nonalcoholic steatohepatitis (NASH) is a common chronic
liver disease that is increasingly prevalent worldwide. Liver
inflammation is an important contributor to
disease progression from
nonalcoholic fatty liver (NAFL) to NASH, but there is a lack of efficient
therapies. In the current study we evaluated the therapeutic potential of
givinostat, a
histone deacetylase (
HDAC) inhibitor, in the treatment of NASH in vivo and in vitro. Liver
inflammation was induced in mice by feeding a
methionine- and
choline-deficient diet (MCD) or a
fructose,
palmitate,
cholesterol diet (FPC). The mice were treated with givoinostat (10 mg·kg-1·d-1, ip) for 8 or 10 weeks. At the end of the experiment, the livers were harvested for analysis. We showed that givoinostat administration significantly alleviated
inflammation and attenuated hepatic
fibrosis in MCD-induced NASH mice.
RNA-seq analysis of liver tissues form MCD-fed mice revealed that
givinostat potently blocked expression of
inflammation-related genes and regulated a broad set of lipid metabolism-related genes. In human
hepatocellular carcinoma cell line HepG2 and human derived fetal hepatocyte cell line L02,
givinostat significantly decreased
palmitic acid-induced intracellular
lipid accumulation. The benefit of
givinostat was further confirmed in FPC-induced NASH mice.
Givinostat administration significantly attenuated hepatic steatosis,
inflammation as well as liver injury in this mouse model. In conclusion,
givinostat is efficacious in reversing diet-induced NASH, and may serve as a therapeutic agent for the treatment of human NASH.